Rate My Professor Christopher Oldmeadow

Conjoint Professor Christopher Oldmeadow is affiliated with the School of Medicine and Public Health in the Faculty of Health and Medicine at the University of Newcastle. He holds a PhD from Queensland University of Technology and a Bachelor of Mathematics (Honours) from the University of Newcastle. As Director of Data Sciences at the Hunter Medical Research Institute, he oversees teams in Biostatistics, Bioinformatics and AI, Data Management, and Health Informatics. Oldmeadow is an applied statistician renowned for coordinating analytic plans across research projects and managing large complex health-related datasets. His expertise extends to fields including cancer, stroke, cardiology, respiratory medicine, surgery, public health, and health services research. Methodologically, he specializes in single-arm trials, parallel-group, crossover, and stepped-wedge designs; biomarker and diagnostic studies; observational studies; registries; and linked administrative data analyses. He applies Bayesian statistics, causal modelling, and techniques for missing data.

Oldmeadow's research focuses on genetic epidemiology, Bayesian statistics, model selection, genomic segmentation, causal modelling, stroke, dementia, smoking cessation, colorectal cancer screening, Aboriginal health, implementation strategies, health behaviors post-stroke, medication safety in dementia, diabetes management, heart failure, musculoskeletal pain, opioid agonist treatment, and cardiovascular disease. He has published first-author articles in Molecular Biology and Evolution, Bioinformatics, and Genetic Epidemiology, and co-authored in Science and Nature Genetics. Notable works include 'Polygenic prediction of educational attainment within and between families from genome-wide association analyses in 3 million individuals' (Nature Genetics, 2022), 'The power of genetic diversity in genome-wide association studies' (Nature Genetics, 2021), 'Trans-ethnic association study of blood pressure determinants in over 750,000 individuals' (Nature Genetics, 2019), and 'Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy for prostate cancer patients with unfavourable intermediate-risk or high-risk disease' from the TROG 03.04 RADAR trial (Lancet Oncology, 2019). As an investigator, he has contributed to grants from 2013 to 2023 on topics such as stroke care, Aboriginal health assessments, smoking cessation in pregnancy, and dementia discharge planning. His high-impact publications and collaborations have advanced genetic research, clinical trials, and public health interventions.